NUWE

Company Overview — What Does Nuwellis, Inc. Do?

Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota. Nuwellis, Inc. (NUWE) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Nestor Jaramillo and employs approximately 70 people, headquartered in EDEN PRAIRIE, Minnesota. With a market capitalization of $3M, NUWE is one of the notable companies in the Healthcare sector.

Nuwellis, Inc. (NUWE) Stock Rating — Avoid (April 2026)

As of April 2026, Nuwellis, Inc. receives a Avoid rating with a composite score of 30.3/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.NUWE ranks #3,923 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Nuwellis, Inc. ranks #670 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

NUWE Stock Price and 52-Week Range

Nuwellis, Inc. (NUWE) currently trades at $1.07. The stock lost $0.01 (0.8%) in the most recent trading session. The 52-week high for NUWE is $25.95, which means the stock is currently trading -95.9% from its annual peak. The 52-week low is $0.19, putting the stock 464.1% above its annual trough. Recent trading volume was 23K shares, suggesting relatively thin trading activity.

Is NUWE Overvalued or Undervalued? — Valuation Analysis

Nuwellis, Inc. (NUWE) carries a value factor score of 7/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 2.29x, compared to the Healthcare sector average of 23.63x — a discount of 90%. The price-to-book ratio stands at 0.99x, versus the sector average of 2.75x. The price-to-sales ratio is 0.32x, compared to 1.66x for the average Healthcare stock.

At current multiples, Nuwellis, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Nuwellis, Inc. Profitability — ROE, Margins, and Quality Score

Nuwellis, Inc. (NUWE) earns a quality factor score of 22/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -485.6%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -208.3% versus the sector average of -33.1%.

On a margin basis, Nuwellis, Inc. reports gross margins of 61.7%, compared to 71.5% for the sector. The operating margin is -128.9% (sector: -66.1%). Net profit margin stands at -191.3%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 1.1% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

NUWE Debt, Balance Sheet, and Financial Health

Nuwellis, Inc. has a debt-to-equity ratio of 133.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 1.71x, suggesting adequate working capital coverage. Total debt on the balance sheet is $0. Cash and equivalents stand at $3M.

NUWE has a beta of -6.40, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Nuwellis, Inc. is 32/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Nuwellis, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Nuwellis, Inc. reported revenue of $8M and earnings per share (EPS) of $-25.39. Net income for the quarter was $-13M. Gross margin was 61.7%. Operating income came in at $-10M.

In FY 2025, Nuwellis, Inc. reported revenue of $8M and earnings per share (EPS) of $-25.39. Net income for the quarter was $-18M. Gross margin was 62.0%. Revenue grew -5.4% year-over-year compared to FY 2024. Operating income came in at $-11M.

In Q3 2025, Nuwellis, Inc. reported revenue of $2M and earnings per share (EPS) of $0.56. Net income for the quarter was $468,000. Gross margin was 65.2%. Revenue grew -6.3% year-over-year compared to Q3 2024. Operating income came in at $-3M.

In Q2 2025, Nuwellis, Inc. reported revenue of $2M and earnings per share (EPS) of $-60.99. Net income for the quarter was $-13M. Gross margin was 55.5%. Revenue grew -21.4% year-over-year compared to Q2 2024. Operating income came in at $-3M.

Over the past 8 quarters, Nuwellis, Inc. has demonstrated a growth trajectory, with revenue expanding from $2M to $8M. Investors analyzing NUWE stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

NUWE Dividend Yield and Income Analysis

Nuwellis, Inc. (NUWE) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

NUWE Momentum and Technical Analysis Profile

Nuwellis, Inc. (NUWE) has a momentum factor score of 38/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 33/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 69/100 reflects moderate short selling activity.

NUWE vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Nuwellis, Inc. (NUWE) ranks #670 out of 838 stocks based on the Blank Capital composite score. This places NUWE in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing NUWE against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full NUWE vs S&P 500 (SPY) comparison to assess how Nuwellis, Inc. stacks up against the broader market across all factor dimensions.

NUWE Next Earnings Date

No upcoming earnings date has been announced for Nuwellis, Inc. (NUWE) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy NUWE? — Investment Thesis Summary

The quantitative profile for Nuwellis, Inc. suggests caution. The quality score of 22/100 flags below-average profitability. The value score of 7/100 indicates premium valuation. Momentum is weak at 38/100, a headwind for near-term performance. High volatility (stability score 32/100) increases portfolio risk.

In summary, Nuwellis, Inc. (NUWE) earns a Avoid rating with a composite score of 30.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on NUWE stock.

Related Resources for NUWE Investors

Explore more research and tools: NUWE vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare NUWE head-to-head with peers: NUWE vs AZN, NUWE vs SLGL, NUWE vs VMD.